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ABSTRACT

Prostasin protein has been found to be a useful marker for
determination of the invasiveness of and as a means to treat
human carcinomas. Using RT-PCR and western blot
analyses, prostasin protein and mRNA expression were
found in normal human prostate epithelial cells and the
human prostate cancer cell line LNCaP, but not in the highly
invasive human prostate cancer cell lines DU-145 and PC-3.
Imunohistochemistry studies of human prostate cancer
specimens revealed a down-regulation of prostasin in highgrade tumors. Using RT-PCR and western blot analyses,
prostasin protein and mRNA expression were found in a
non-invasive human breast cancer cell line, MCF-7, while
invasive human breast cancer cell lines MDA-MB-231 and
MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast
cancer cell line, MDA-MB-453, was shown to express
prostasin mRNA but not prostasin protein. Transfection of
DU-145 and PC-3 cells with a full-length human prostasin
cDNArestored prostasin expression and reduced the in vitro
invasiveness by 68% and 42%, respectively. Transfection of
MDA-MB-231 and MDA-MB-435s cells with a full-length
human prostasin cDNA restored prostasin expression and
reduced the in vitro invasiveness by 50% for either cell line.
The prostasin gene promoter region was found to be hypermethylated at specific sites in invasive cancer cells.
7 Claims, 9 Drawing Sheets
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1
METHOD OF IDENTIFYING AND

TREATING INVASIVE CARCINOMAS
This invention relates to prostasin and its use in the
diagnosis and treatment of prostate and breast cancers, and
is a Continuation-In-Part (CIP) of application Ser. No.
09/755,811 filed Jan. 5, 2001 now U.S. Pat. No. 6,569,684
and claims the priority to U.S. Provisional application Ser.
No. 60/174,801 filed Jan. 6, 2000 and was supported in part
by Department of Defense Prostate Cancer Research Grant
DAMD17-98-l-8590, and in part by grants to principal
investigator K. X. CHAI from the Florida Hospital Gala
Endowed Program for Oncologic Research.
BACKGROUND AND PRIOR ART
For men in the U.S. prostate cancer is the most commonly
diagnosed cancer, and the second leading cause of cancerrelated death (Greenlee RT, Murray F. Bolden S, Wingo P
A Cancer statistics, 1999. Ca: a Cancer Journal for Clinicians 2000;50:7-33). Prostate cancers originate as localized
lesions; some of these localized lesions will progress to
become invasive, migratory and metastatic. Our current
understanding of the mechanisms of the prostate cancer
invasion process, however, is poor. Our ability to predict the
acquisition of invasive potentials by a prostate cancer is
limited.
The mechanisms leading to the development of a prostate
cancer are complex. Currently, it is believed to be the result
of multiple transformation steps from normal prostate glandular cells (Carter H B. Piantadosi S. Isaacs J T. Clinical
evidence for and implications of the multistep development
of prostate cancer. Journal of Urology. 143(4):742-6, 1990).
The initial steps result in what are described as prostatic
interepithelial neoplastic (PIN) lesions (Isaacs J T. Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate
cancer. [Review] [92 refs] American Journal of Pathology.
150(5):1511-21, 1997). These PIN lesions may then typically have three different fates based on an assessment of
their impact to the patient. The PIN lesions can remain as
such, not producing histologically detectable prostate
cancer, or further transform into histologically detectable
prostate cancer. Most of the histologically detectable prostate cancers will be asymptomatic in the patient and remain
non-manifest clinically as many are discovered post-mortem
(Carter H Coffey D. Prostate Cancer: the magnitude of the
problem in the United States. In a Multidisciplinary Analysis
of Controversies in the Management of Prostate Cancer.
(Eds. Coffey D. Resnick M. Door R. et al.), ppl-9, Plenum
Press, 1988; Carter H B Piantadosi S. Issacs J T. Clinical
evidence for implications of the multistep development of
prostate cancer. Journal of Urology. 143(4):742-6, 1990;
Scardino P T. Weaver R. Hudson M A Early detection of
prostate cancer. [Review] [102 refs] Human Pathology.
23(3):211-22, 1999). Prostate cancers are diagnosed clinically by an estimate of size and location using the TNM
staging system (Denis L J. Staging and prognosis of prostate
cancer. European Urology. 24 Suppl 2:13-8, 1993), and by
pathological staging based on an examination of the histology of the removed prostate via either biopsy or prostatectomy using a system by D. F. Gleason, (Gleason D F.
Classification of prostatic carcinomas. Cancer Chemotherapy Reports-Part 1. 50(3):125-8, 1966). About 50% of
prostate cancer cases receiving treatment are diagnosed
clinically as advanced, or, non-organ-confined (Scardino P
T. Weaver R. Hudson M A Early detection of prostate
cancer. [Review] [102 refs] Human Pathology. 23(3):

2
211-22, 1992), for which no effective treatment exists
(Yagoda A Petrylak D. Cytotoxic chemotherapy for
advanced hormone-resistant prostate cancer. [Review] [ 63
refs] Cancer. 71(3 Suppl): 1098-109, 1993 and Petrylak,
5 1993). Of the remaining 50% cases, 1/3 (-50,000) are diagnosed as organ-confined but micrometastasis may be
present. The final group of patients (-100,000) have truly
organ-confined prostate cancer and can be cured by radical
prostatectomy (Sgrignoli AR Walsh P C. Steinberg G D.
10 Steiner M S. Epstein J I. Prognostic factors in men with
stage D 1 prostate cancer: identification of patients less
likely to have prolonged survival after radical prostatectomy
[see comments]. Journal of Urology. 152(4):1077-81, 1994;
Zincke H. Oesterling J E. Blute ML. Bergstralh E J. Myers
15 R P. Barrett D M. long term (15 years) results after radical
prostatectomy for clinically localized (stageT2c or lower)
prostate cancer [see comments]. Journal of Urology.152(5 Pt
2): 1850--7, 1994) or left untreated (watchful waiting) without the risk of life-threatening or life-altering. For the
20 patients with non-organ-confined prostate cancers
(discovered via either biopsy or surgery), undergoing systemic treatment early is essential to the management of their
cancer (Yagoda A Petrylak D. Cytotixic chemotherapy for
1098-109, 1993). Consequently, it will be ideal, both medi25 cally and economically, if one could precisely predict upon
early pathological examination of the tumor, which group of
patients will have truly organ-confined disease versus which
group will have invasive prostate cancer.
Clinical staging of prostate cancer generally depends on
30 the results of three tests that are performed in the following
order: a PSA (prostate-specific antigen) blood test as a
screening method; DRE (digital rectal examination) for an
initial indication of palpable disease; and, a biopsy to obtain
samples for histological examination. Prostate cancers,
35 removed either via biopsy or surgery, are graded histologically by the system of Gleason. (Gleason D F. Classification
of prostatic carcinomas. Cancer Chemotherapy ReportsPartl. 50(3):125-8, 1966), which is an evaluation of how
aggressive and how poorly-differentiated the prostate can40 cers are. The aggressiveness of prostate tumors: of low
Gleason scores ( <5) is limited; of high Gleason scores
(8-10) are highly aggressive; but, for the intermediate
Gleason-score (5-7) prostate cancers (76% of prostate
tumors), the accuracy of predicting their aggressiveness is
45 poor (Gleason D F. Mellinger GT. Prediction of prognosis
for prostatic adenocarcinoma by combined histological
grading and clinical staging. Journal of Urology. 111(1):
58-64, 1974). Thus, the ability to accurately determine the
aggressiveness of these intermediate Gleason-score prostate
50 tumors has remained as a practical challenge to, and a
primary goal for, prostate cancer research (Isaacs J T.
Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of
prostate cancer. [Review] [92 refs] American Journal of
55 Pathology. 150(5):1511-21, 1997). Especially with regard to
the number of patients (150,000) facing a decision of
whether to undergo systemic treatment, the most urgent
demand in prostate cancer care is the development of
methods to enhance our ability to accurately predict the
60 aggressiveness of the tumors with Gleason scores of 5-7.
It is now commonly believed that cancers occur via
multiple transformation steps by accumulating mutations in
three classes of genes: proto-oncogenes (Park M. Oncogenes. In The Genetic Basis of Human Cancer (Eds. Vogel65 stein Band Kinzler KW), pp205-28, McGraw-Hill Health
Professions Divisions, 1998); tumor-suppressor genes
(Knuutila S. Aalto Y. Bjorkqvist AM. EL-Rifai W. Hemmer
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S. Huhta T. Kettunen E. Kiuru-Kuhlefelt S. Larramendy
patients with prostate cancer. Cancer Research. 54(14):
ML. Lushnikova T. Manni 0. Pere H. Tapper J. Tarkkanen
3929-33, 1994); ~ic integrin (Formaro M. Tallini G. BofeM. Varis A Wasenius V M. Wolf M. Zhu Y. DNA copy
tiado CJ. Bosari S. Languino LR. Down-regulation of ~lC
number losses in human neoplasms. [Review] [197 refs]
integrin, an inhibitor of cell proliferation, in prostate carciAmerican Journal of Pathology. 155(3):683-94, 1999); and, 5 noma. American Journal of Pathology. 149(3):765-73,1996
DNA repair genes (Knuutila S. Aslto Y. Bjorkqvit A M.
Formaro M. Manzotti M. Tallini G. Stear A E. Bosari S.
EL-Rifai W. Hemmer S. Huhta T. Kettunen E. KiuruRuoslahti E. Languino LR. ~lC integrin in epithelial cells
Kuhlefelt S. Larramedy ML. Lushnikova T. Manni 0. Pere
correlates with a nonproliferative phenotype: forced expresH. Tapper J. Tarkkanen M. Varis A Wasenius V M. Wolf M.
sion of ~lC inhibits prostate epithelial cell proliferation.
Zhu Y. DNA copy number losses in human neoplasms. 10 American Journal of Pathology. 153(4):1079-87, 1998; p27
[Review] [197 refs] American Journal of Pathology. 155(3):
(kipl) (Tsihlias J. Kapusta LR. DeBoer G. Morava-Protzner
683-94, 1999). The histological prostate cancers for which
I. Zbieranowski I. Bhattacharya N. Catzavelos G C. Klotz L
the prediction of clinical aggressiveness is difficult (those
H. Slingerland JM. Loss of cyclin-dependent kinase inhibiwith the intermediate Gleason scores 5-7) probably have not
tor p27Kipl is a novel prognostic factor in localized human
gone through the necessary "multi-step" transformation to 15 prostate adenocarcinoma. Cancer Research. 58(3):542-8,
acquire the potentials to behave aggressively (as would the
1998); and CD44 (Lou W. Krill D. Dhir R. Becich M J. Dong
high-grade cancers). This notion was supported by studies
J T. Frierson H F Jr. Isaacs W B. Isaacs J T. Gao A C.
comparing the course of prostate cancer development among
Methylation of the CD44 metastasis suppressor gene in
men in Japan and in the U.S., and Japanese men who
human prostate cancer. Cancer Research. 59(10):2329-31,
migrated to the U.S. (Carter H B. Piantadosi S. Isaacs J T. 20 1999). By using the method of immunohistochemistry, these
Clinical evidence for and implications of the multistep
genes were found to be down-regulated in prostate cancer.
development of prostate cancer. Journal of Urology, 1990;
KAI's down regulation is a potential predictor of metastasis
Haenszel W. Kurihara M. Studies of Japanese Migrants. 1.
(Dong, et al., 1996: Ueda et al., 1996). While
Mortality form cancer and other diseases among Japanese in
E-cadherin'cadherin's down regulation is strongly correthe United States. Journal of the National Cancer Institute.40 25 lated to higher Gleason grades. Functional studies of these
(1):43-68, 1968; Akazaki K. Stemmerman G N. Comparargenes have given clues to their role in prostate cancer or
tive study of latent carcinoma of the prostate among Japanormal prostate biology. (Debruyne F M. Isaacs W B.
nese in Japan and Hawaii. Journal of the National Cancer
Expression of the cellular adhesion molecule E-cadherin is
Institute. 50(5):1137-44, 1973; Dunn J E. Cancer epidemireduced or absent in high-grade prostate cancer. Cancer
ology in populations of the United States-with emphasis on 30 Research. 52(18):5104-9, 1992; Umbas R. Isaacs W B.
Hawaii and California-and Japan. Cancer Research. 35(11
Bringuier P P. Schaafsma H E. Karthaus H F. Oosterhof G
Pt.2):3240-5, 1975). The findings were that first- and
0. Debruyne F M. Schalken J A Decreased E-cadherin
second-generation Japanese men who migrated to the U.S.
expression is associated with poor prognosis in patients with
have a higher prostate cancer incident rate than native
prostate cancer. Cancer Research. 54(14):3929-33, 1994;
Japanese men. The emigrant Japanese men's prostate cancer 35 metastasis suppressor gene during the progression of human
incident rate is similar to that of men in the U.S. Investiprostatic cancer infrequently involves gene mutation or
gating the changes of expression in these three classes of
allelic loss. Cancer Research. 56(19):4387-90; 1996 Ueda T.
cancer-relevant genes during the course of prostate cancer
Ichikawa T. Tamaru J. Mikata A Akakura K. Akimoto S.
development will lead to a better understanding of the
Imai T. Yoshie 0. Shiraishi T. Yatani R. Ito H. Shimazaki J.
processes by which prostate cancers acquire their aggressive 40 Expression of the KAil protein in benign prostatic hyperpotentials. The discovery of molecules whose changes can
plasia and prostate cancer. American Journal of Pathology.
be correlated to the staging of prostate cancer will provide
149(5): 1435-40, 1996) while E-cadherin's down-regulation
new tools to improve our ability to better predict the
is strongly correlated to higher Gleason grades (Umbas R.
aggressive behaviors of prostate cancer. This approach is
Schalken J A Aalders T W. Carter B S. Karthaus H F.
now commonly referred to as "molecular staging".
45 Schaafsma H E. Debruyne F M. Isaacs W B. Expression of
the cellular adhesion molecule E-cadherin is reduced or
Down-regulated genes such as tumor suppressors, invaabsent in high-grade prostate cancer. Cancer Research.
sion suppressors or metastasis suppressors may be used as
52(18):5104-9,1992; Umbas R. Isaacs W B. Bringuier P P.
prostate cancer markers. Examples of these genes that can
Schaafsma HE. Karthaus HF. Oosterhof G 0. Debruyne F
potentially serve as prostate cancer markers for "molecular
staging" are: KAii (Dong J T. Suzuki H. Pin S S. Bova GS., 50 M. Schalken J A Decreased E-cadherin expression is assoSchalken JA, Issacs W B, Barrett JC. Issace I T. Downciated with poor prognosis in patients with prostate cancer.
regulation of the KAI I metastasis suppressor gene during
Cancer Research. 54(14):3929-33, 1994) Functional studies
the progression of human prostatic cancer infrequently
of these genes have given clues to their role in prostate
involves gene mutation or allelic loss. Cancer Research.
cancer or normal prostate biology. Human KAI suppress
56(19): 4387-90, 1996); (Ueda T, Ichikawa T., Tamaru j, 55 metastasis of rat prostate cancer cells upon gene transfer
Mikata A, Akakura K, Akimoto S, Imai T. Yoshie 0.
(Dong J T. Lamb PW. Rinker-Schaeffer CW. Vukanovic J.
Shiraishi T. Yatani R. Ito H. Shimazaki J., Expression fof the
Ichikawa T. Isaacs J T. Barrett J C. KAil, a metastasis
KAH protein in benign prostatic hyperplasia and prostate
suppressor gene for prostate cancer on human chromosome
llpll.2 [see comments]. Science. 268(5212):884-6,1995).
cancer. American Journal of Pathology 149(5): 1435-40,
1996); E-cadherin (Umbas R. Isaacs WB BringuierP P. 60 ~ic and p27(kipl) are involved in signaling pathway that
Schaafsma HE. Karthaus HF. Oosterhof G 0. Debruyne F
inhibits cell proliferation (Formaro M. Tallini G. Zheng D Q.
Flanagan W M. Manzotti M. Languino L R. p27(kipl) acts
M. Schalken J A Decreased E-Cadherin expression is
associated with poor prognosis is patients with prostate
as a downstream effector of and is coexpressed with the
cancer. Cancer Research. 52(18):5104-9, 1992, Umbas R.
betalC integrin in prostatic adenocarcinoma. Journal of
Isaacs W B. Bringuier P P. Schaafsma H E. Karthaus H F. 65 Clinical Investigation. 103(3):321-9, 1999). E-cadherin
Oosterhof G 0. Debruyne F M. Schalken J A Decreased
expression is progressively lost during the transformation of
rat prostate cancer from non-invasive to invasive
E-cadherin expression is associated with poor prognosis in
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(Bussemakers M J. van Moorselaar R J. Giroldi L A
noma in situ (hereinafter indicated as DCIS) incidence has
increased dramatically since 1983 as a result of implementIchikawa T. Isaacs J T. Takeichi M. Debruyne FM. Schalken
ing screening programs (Ernster V L. Barclay J. Increases in
J A. Decreased expression of E-cadherin in the progression
ductal carcinoma in situ (DCIS) of the breast in relation to
of rat prostatic cancer. Cancer Research. 52(10):2916-22,
1992), and it has also been shown to be an invasion 5 mammography: a dilemma. [Review] [34 refs] Journal of
the National Cancer Institute. Monographs.
suppressor (Lou W. Krill D. Dhir R. Becich M J. Dong J T.
Frierson H F Jr. Isaacs W B. Isaacs J T. Gao A C. Methy(22): 151-6, 1997). DCIS is described as a malignant
lation of the CD44 metastasis suppressor gene in human
growth of epithelial cells within the ducts and lobules of the
prostate cancer. Cancer Research. 59(10):2329-31, 1999).
breast, and is believed to be the precursor of all invasive
CD44 loss of expression is associated with high metastatic 10 breast carcinoma. DCIS itself is non-life-threatening;
ability and transfection of CD44 suppresses metastasis withhowever, current treatment options for DCIS include
masectomy, lumpectomy, radiotherapy or tamoxifen
out affecting tumorigenecity of rat prostate cancer cells (Gao
(Ernster V L. Barclay J. Increases in ductal carcinoma in situ
A C. Lou W. Dong J T. Isaacs J T. CD44 is a metastasis
suppressor gene for prostatic cancer located on human
(DCIS) of the breast in relation to mammography: a
chromosome llp13. Cancer Research. 57(5):846-9, 1997). 15 dilemma. [Review] [34 refs] Journal of the National Cancer
CD44 down-regulation is a prognostic marker for prostate
Institute. Monographs. (22): 151-6, 1997; Hwang E S.
cancer (Noordzij MA van Steenbrugge G J. Verkaik N S.
Esserman L J. Management of ductal carcinoma in situ.
Schroder F H. van der Kwast TH. The prognostic value of
[Review] [91 refs] Surgical Clinics of North America.
CD44 isoforms in prostate cancer patients treated by radical
79(5):1007-30, viii, 1999). These treatment options for
prostatectomy. Clinical Cancer Research. 3(5):805-15, 20 DCIS are at best controversial due primarily to a lack of
1997). Human prostate cancer histology is heterogeneous, or
precision in diagnosis and prognosis of whether the detected
"multi-focal" in nature (Isaacs JT. Bova GS. Prostate CanDCIS will progress to invasive breast cancer and whether
recurrence is likely after treatment, usually with a high
cer. In The Genetic Basis of Human Cancer (Eds. Vogelstein
percentage being invasive breast cancer (Zaugg K. Bodis S.
B and Kinzler KW), pp653-60, McGraw-Hill Health Professions Division, 1998 and Bova, 1998), with an average of 25 Is there a role for molecular prognostic factors in the clinical
management of ductal carcinoma in situ (DCIS) of the
five lesions in a patient (Bastacky SI. Wojno KJ. Walsh PC.
Carmichael M J. Epstein J I. Pathological features of heredibreast?. [Review] [ 49 refs] Radiotherapy & Oncology.
tary prostate cancer. Journal of Urology. 153(3 Pt 2):987-92,
55(2):95-9, 2000). At present, histological grading (nuclear
1995). Between the tumor regions of a prostate and within
grading and whether come do-type necrosis is present) and
a single tumor region, the genetic causes to the cancer are 30 the size of the DCIS are used to provide assessments of risk
of DCIS to progress into invasive breast cancer (Zaugg K.
heterogeneous and independent as well (Sakr WA Macoska
J A Benson P. Grignon D J. Wolman S R. Pontes J E.
Bodis S. Is there a role for molecular prognostic factors in
Crissman J D. Allelic loss in locally metastatic, multithe clinical management of ductal carcinoma in situ (DCIS)
of the breast?. [Review] [ 49 refs] Radiotherapy & Oncology.
sampled prostate cancer. Cancer Research. 54(12):3273-7,
1994; Qian J. Bostwick D G. Takahashi S. Borell T J. Herath 35 55(2):95-9, 2000; Shaker BS. Sloane JP. DCIS grading
schemes and clinical implications. [Review] [ 40 refs] HisJ F. Lieber M M. Jenkins R B. Chromosomal anomalies in
prostatic intraepithelial neoplasia and carcinoma detected by
topathology. 35(5):393-400, 19; van de Vijver M J. Ductal
carcinoma in situ of the breast: histological classification
fluorescence in situ hybridization. Cancer Research. 55(22):
5408-14, 1995; Mirchandani D. Zheng 1. Miller G J. Ghosh
and genetic alterations. [Review] 169 refs] Recent Results in
AK. Shibata D K. Cote R J. Roy-Burman P. Heterogeneity 40 Cancer Research. 152:123-34, 1998). These parameters are
in intratumor distribution of p53 mutations in human prosfar from being adequate for making the most accurate choice
tate cancer. American Journal of Pathology. 147(1):92-101,
of treatment, resulting in a choice either overly excessive or
conservative, in either case, the patient will suffer unneces1995). In the end, the best predictor of prostate cancer's
potential to gain invasiveness may be a consideration of a
sarily. Molecular markers can help improve our ability to
number of genes whose expression levels change along the 45 better diagnose DCIS and stratify treatment options, especourse of cancer development, as demonstrated in principle
cially the molecular markers that, themselves, play a role in
by Greene et al. (Greene G F. Kitadai Y. Pettaway CA von
the progression of DCIS to invasive breast cancer (Zaugg K.
Eschenbach AC. Buucana C D. Fidler I J. Correlation of
Bodis S. Is there a role for molecular prognostic factors in
the clinical management of ductal carcinoma in situ (DCIS)
metastasis-related gene expression with metastatic potential
in human prostate carcinoma cells implanted in nude mice 50 of the breast?. [Review] [ 49 refs] Radiotherapy & Oncology.
using an in situ messenger RNA hybridization technique.
55(2):95-9, 2000; Silverstein M J. Masetti R. Hypothesis
American Journal of Pathology. 150(5):1571-82, 1997).
and practice: are there several types of treatment for ductal
Hence, expanding the repertory of such genes, including
carcinoma in situ of the breast?. [Review] [ 53 refs] Recent
Results in Cancer Research. 152:105-22, 1998). The tumboth the onco-genes and the suppressor genes, will enhance
the accuracy and dependability of this approach. As for the 55 origenesis process is a multi-step transformation in which
treatment options of prostate cancer, patients with truly
molecular events escalate to the final stage of invasive
organ-confined prostate cancer can be cured by radical
phenotype (Silverstein MJ. Masetti R. Hypothesis and pracprostatectomy. Patients with non-organ-confined prostate
tice: are there several types of treatment for ductal carcicancers, however, have very low survival rates and the
noma in situ of the breast?. [Review] [ 53 refs] Recent
current treatments are largely ineffective (Yagoda A Petry- 60 Results in Cancer Research. 152:105-22, 1998). The conventional paradigm of protease involvement in the devellak D. Cytotoxic chemotherapy for advanced hormoneresistant prostate cancer. [Review] [63 refs] Cancer. 71(3
opment and progression of cancer has been the assignment
Suppl): 1098-109, 1993). Breast cancer is the most diagof a usually negative role to the proteases, such as promoting
nosed cancer in women and the second leading cancer
tumor invasion (Mignatti P. Rifkin D B. Biology and biorelated cause of death in women (Greenlee RT, Murray T, 65 chemistry of proteinases in tumor invasion. [Review] [306
Bolden S, Wingo PA Cancer statistics, 1999. Ca: a Cancer
refs] Physiological Reviews. 73(1):161-95, 1993). In turn,
Journal for Clinicians 2000;50:7-33). Breast ductal carcithe conventional paradigm of protease inhibitors in relation
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to cancer is usually regard of a beneficial effect for the
of Biological Chemistry. 269(29):18843-8, 1994; (Yu JX.
presence of these molecules (Kennedy AR. ChemoprevenChao L. Chao J. Molecular cloning, tissue-specific
tive agents: protease inhibitors. Pharmacol Therapeut
expression, and cellular localization of human prostasin
78:167-209, 1998). Recently, however, the picture of a new
mRNA. Journal of Biological Chemistry. 270(22):13483-9,
paradigm is beginning to emerge for several serine proteases 5 1995). Molecular cloning of a full-length human prostasin
in breast, prostate, and testicular cancers. A "normal epithecDNA revealed that its predicted amino acid residue
lial cell specific-1" (NESl) serine protease was found to be
sequence contains a carboxyl-terminal hydrophobic region
that can potentially anchor the protein on the membrane (Yu
down-regulated in breast and prostate cancers, and it funcJXChao L. Chao J. Molecular cloning, tissue-specific
tions as a tumor suppressor (Goyal J, Smith KM, Cowan J
M, Wazer D E, Lee S W, Band V. The role for NESl serine 10 expression, and cellular localization of human prostasin
protease as a novel tumor suppressor. Cancer Res
mRNA. Journal of Biological Chemistry. 270(22):13483-9,
58:4782-4786, 1998). A prostate-specific serine protease,
1995). At the amino acid level, prostasin is similar to plasma
prostase (Nelson P S. Gan L. Ferguson C. Moss P. Gelinas
kallikrein, coagulation factor XI, hepsin, plasminogen,
R. Hood L. Wang K. Molecular cloning and characterization
acrosin, prostase, and, in particular, testisin (sharing 44%
of prostase, an androgen-regulated serine protease with 15 sequence identity) [Nelson PS. Gan L. Ferguson C. Moss P.
prostate-restricted expression. Proceedings of the National
Gelinas R. Hood L. Wang K. Molecular cloning and charAcademy of Sciences of the United States of America.
acterization of prostase, an androgen-regulated serine pro96(6):3114-9, 1999), was shown to be expressed in normal
tease with prostate-restricted expression. Proceedings of the
prostate but not in prostate cancer cell lines DU-145 and
National Academy of Sciences of the United States of
PC-3. The expression of a testis-specific serine protease, 20 America 96(6):3114-9, 1999; Hooper J D. Nicol D L.
testisin, was shown to be lost in testicular cancer through
Dickinson J L. Eyre HJ. ScarmanAL. Normy le J F. Stuttgen
either a loss of gene (Hooper JD. Nicol D L. Dickinson J L.
MA Douglas M L. Loveland KA Sutherland G R. Antalis
Eyre HJ. ScarmanAL. Normyle J F. Stuttgen MA Douglas
T M. Testisin, a new human serine proteinase expressed by
M L. Loveland KA Sutherland G R. Antalis T M. Testisin,
premeiotic testicular germ cells and lost in testicular germ
a new human serine proteinase expressed by premeiotic 25 cell tumors. Cancer Research. 59(13):3199-205, 1999; Yu
testicular germ cells and lost in testicular germ cell tumors.
JX. Chao L. Chao J. Molecular cloning, tissue-specific
Cancer Research. 59(13):3199-205, 1999) or methylation in
expression, and cellular localization of human prostasin
the promoter (Boucaut K, Douglas M, Clements J, Antalis T.
mRNA. Journal of Biological sodium channel-activating
The serine proteinase testisin may act as a tumor and/or
protease (CAPl) was shown to be highly homologous to
growth suppressor in the testis and may be regulated by 30 human prostasin as well (sharing 53% sequence identity at
DNA methylation. Cancer Genetics and Tumor Suppressor
the amino acid level) (Vallet V. Chraibi A Gaeggeler H P.
Horisberger JD. Rossier B C. An epithelial serine protease
Genes, Cold Spring Harbor Laboratory, 2000). Further,
activates the amiloride-sensitive sodium channel. Nature.
transfection of human testicular cancer cells with a testisin
cDNAreduced the tumor growth of xenografts of these cells
389(6651):607-10, 1997). Prostasin is encoded by a singlein nude mice, suggesting a tumor suppressor function for 35 copied gene, which is located on human chromosome 16pl
testisin (Boucaut K, Douglas M, Clements J, Antalis T. The
1.2 (Yu JX. Chao L. Ward D C. Chao J. Structure and
serine proteinase testisin may act as a tumor and/or growth
chromosomal localization of the human prostasin (PRSS8)
suppressor in the testis and may be regulated by DNA
gene. Genomics. 32(3):334-40,1996). The secreted prostasin cleaves synthetic substrates in vitro preferentially at the
methylation. Cancer Genetics and Tumor Suppressor Genes,
Cold Spring Harbor Laboratory, 2000). The testisin serine 40 carboxyl-terminal side ofArg residue, and is thus considered
protease is potentially membrane-bound as suggested by its
a trypsin-like serine protease (Yu JX. Chao L. Chao J.
structure and confirmed by immunohistochemistry gene
Prostasin is a novel human serine proteinase from seminal
fluid. Purification, tissue distribution, and localization in
(Hooper JD. Nicol D L. Dickinson J L. Eyre HJ. Scarman
prostate gland. Journal of Biological Chemistry. 269(29):
AL. Normy le J F. Stungen MA Douglas M L. Loveland K
A Sutherland GR. Antalis TM. Testisin, a new human serine 45 18843-8, 1994). The physiological function of prostasin,
proteinase expressed by premeiotic testicular germ cells and
however, has remained unknown. By comparing gene
lost in testicular germ cell tumors. Cancer Research. 59(13):
expression of normal tissues, pre-invasive cancer, and inva3199-205, 1999.) Prostasin serine protease is an acidic
sive cancer, it would be highly advantageous to discover
protein (pl 4.5-4.8) of approximately 40 kDa in molecular
molecular markers that display a differential expression
mess (Yu JX. Chao L. Chao J. Prostasin is a novel human 50 pattern between the pre-invasive and the invasive phenoserine proteinase from seminal fluid. Purification, tissue
types and use these markers for a more precise diagnosis and
distribution, and localization in prostate gland. Journal of
prognosis of prostate and/or breast cancers. With the
enhanced precision in diagnosis and prognosis, treatment
Biological Chemistry. 269(29):18843-8, 1994). It is preoptions for patients with DCIS could then be stratified.
dominantly made in the prostate gland (-146 ng/mg
protein), with lesser amounts (2-6 ng/mg protein) also found 55 Those with low risks of developing invasive breast cancer
in the bronchi, colon, kidney, liver, lung, pancreas, and the
will have a higher confidence in choosing breast-conserving
salivary glands (Yu JX. Chao L. Chao J. Prostasin is a novel
options, while those at high risks will ponder more aggreshuman serine proteinase from seminal fluid. Purification,
sive options with the necessary follow-up treatments.
tissue distribution, and localization in prostate gland. Journal
Similarly, those males with low risks of developing invasive
of Biological Chemistry. 269(29):18843-8, 1994). Prostasin 60 prostate cancer will have a higher confidence in choosing
is secreted in the prostatic fluid, and can be detected in the
prostate-conserving options, while those at high risks will
semen (-9 µg/ml). Prostasin expression is localized to the
ponder more aggressive options with the necessary followup treatments.
epithelial cells of human prostate gland by in situ hybridization histochemistry using an antibody or an anti-sense
SUMMARY OF THE INVENTION
RNA probe (Yu J X. Chao L. Chao J. Prostasin is a novel 65
human serine proteinase from seminal fluid. Purification,
The first objective of the present invention is to reduce
tissue distribution, and localization in prostate gland. Journal
deficiencies in the prior art with specific regard to differen-
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tial diagnosis of invasive prostate and breast cancers and to
FIG. 2 is a diagrammatic representation of the analysis of
treatment of invasive and metastatic prostate and breast
prostasin indicative of the absence or existence, or of the
cancers.
invasiveness of human mammary carcinoma
The second objective of the present invention is to proFIG. 3 shows human prostasin expression in prostate
vide a new marker for prostate and breast cancer.
5 epithelial cells.
The third objective of the invention is to provide as a drug
FIG. 4A shows immunohistochemical detection of prosto patients with carcinoma of the prostate via delivery of a
tasin protein in benign human prostate tissues.
functional prostasin gene.
FIG. 4B is an enlarged view of the boxed region of FIG.
The fourth objective of the invention is to provide as a
drug to patients with carcinoma of the prostate via delivery 10 4A.
of a functional prostasin cDNA.
FIG. 4C shows immunohistochemistry of benign human
prostate tissues with prostasin antibody omitted in the
The fifth objective of the invention is to provide as a drug
to patients with carcinoma of the breast via delivery of a
procedures, no epithelial cells displayed any staining.
functional prostasin gene.
FIG. 4D is an enlarged view of the boxed region of FIG.
The sixth objective of the invention is to provide as a drug 15 4C.
to patients with carcinoma of the breast via delivery of a
FIG. 4E shows immunohistochemistry of human prostate
functional prostasin cDNA.
tumor with prostasin antibody omitted in the procedures, no
This invention identifies prostasin serine protease as a
epithelial cells displayed any staining.
potential marker, and as a tumor invasion suppressor for
FIG. 4F shows immunohistochemical detection of prosprostate and breast cancers and thus provides methods (a),
(b), .and (c) of determining invasiveness levels of human 20 tasin protein in benign human prostate tissue surrounded by
prostate carcinomas.
carcmomas:
FIG. 4G shows immunohistochemical detection of pros(a) using prostasin protein levels, comprising the steps of:
sampling a human carcinoma tissue; determining prostasin protein in Gleason grade 2 prostate tumor.
FIG. 4H is an enlarged view of the boxed region of FIG.
25
th:n
4G.
antibody to said tissue wherein the reagent-antibody
FIG. 4I shows immunohistochemical detection of prostabecomes bound to prostasin protein in said tissue, and
sin protein in Gleason grade 3 prostate tumor.
determining invasiveness of the human carcinoma tisFIG. 41 is an enlarged view of the boxed region of FIG.
sue based on the prostasin protein levels:. or
(b) using prostasin mRNA levels, comprising the steps of: 30 41.
sampling a human carcinoma tissue; determining prosFIG. 4K shows immunohistochemical detection of prostasin mRNA levels in the human carcinoma tissue
tasin protein in Gleason grade 4 prostate tumor.
preferably by applying prostasin-specific anti-sense
FIG. 4L is an enlarged view of the boxed region of FIG.
RNA probes in an in situ hybridization to determine the
4K.
prostasin mRNA levels in the separated human carci- 35
FIG. 5 shows human prostasin expression in human breast
noma tissue the determination of the prostasin mRNA
cancer cell lines.
levels in the separated human carcinoma sample tissue;
FIG. 6 shows promoter hypermethylation of the human
to make possible and determining invasiveness of the
prostasin gene in human prostate and breast cancer cell lines.
human carcinoma tissue based on the prostasin mRNA
FIG. 7 shows prostasin protein expression and in vitro
40
levels; or
invasive properties of the DU-145 and the PC-3 transfec(c) using prostasin gene promoter DNA methylation
tants.
levels, comprising the steps of: sampling a human
FIG. 8 shows prostasin protein expression and in vitro
carcinoma tissue; determining prostasin gene promoter
invasive properties of the MDA-MB-231 and the MDADNA methylation levels in the human carcinoma
tissue, preferably by applying prostasin-promoter- 45 MB-435s transfectants.
specific oligonucleotide primers in a PCR to determine
FIG. 9a Is a schematic illustration of the promoter-exon
the prostasin gene promoter DNAmethylation levels in
region of the prostasin gene.
the sampled human carcinoma tissue and determining
FIG. 9b shows a genomic Southern blot analysis of DNA
invasiveness of the human carcinoma tissue based on
from NHMEC and human breast cancer cell lines.
the prostasin gene promoter DNA methylation levels, 50
FIG. 9c shows a genomic Southern blot analysis of
as well as a method of treating invasive human carcinoMDA-MB-231 and MDA-MB-435s cells following demmas comprising the steps of: incorporating human
ethylation.
prostasin nucleic acid into a selected gene delivery
FIG. 10 shows DNA sequence and the deduced ammo
vector nucleic acid to form a recombinant nucleic acid;
acid sequence of the PRSS8 (prostasin) gene.
preferably wherein the nucleic acid includes a gene or 55
cDNA delivering the recombinant nucleic acid into a
DESCRIPTION OF THE PREFERRED
human carcinoma; and reducing invasiveness of the
EMBODIMENT
human carcinoma.
Before explaining the disclosed embodiment of the
Further objects and advantages of this invention will be
apparent from the following detailed description of a pres- 60 present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
ently preferred embodiment, which is illustrated schematiparticular arrangement shown since the invention is capable
cally in the accompanying drawings.
of other embodiments. Also, the terminology used herein is
BRIEF DESCRIPTION OF THE FIGURE
for the purpose of description and not of limitation.
Using RT-PCR and western blot analyses, prostasin proFIG. 1 is a diagrammatic representation of the analysis of 65
prostasin indicative of the absence or existence, or of the
tein and mRNA expression were found in normal human
invasiveness of human prostate carcinoma.
prostate epithelial cells and the human prostate cancer cell
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line LNCaP, but discovered not present in the highly invathe potential invasiveness of prostate tumors. The supportsive human prostate cancer cell lines DU-145 and PC-3.
ing evidence came from our findings that two invasive
human prostate cancer cell lines DU-145 and PC-3 do not
Immunohistochemistry studies of human prostate cancer
express prostasin while normal prostate epithelial cells and
specimens revealed a down-regulation of prostasin in highgrade tumors.
5 a non-invasive prostate cancer cell line LNCaP express both
the prostasin mRNA and protein.
Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in a non-invasive
Refer now to FIG. 3 which shows human prostasin
human breast cancer cell line, MCF-7, while invasive human
expression in prostate epithelial cells. By means of western
breast cancer cell lines MDA-MB-231 and MDA-MB-435s
blot analysis (upper panel), prostasin (as a 40-kDa band) was
were also discovered not to express either the prostasin 10 detected in normal human prostate epithelial cells (CCprotein or the mRNA. A non-invasive human breast cancer
2555) and the LNCaP cells, but not in the DU-145 or PC-3
cells. An equal amount of total protein (100 µg) was loaded
cell line, MDA-MB-453, was shown to express prostasin
for each sample. At the mRNA level, human prostasin
mRNA but not prostasin protein. Examination of the prosmRNA (via a 232-bp amplified DNA band) was detected in
tasin gene promoter in the human prostate and breast cancer
cell lines by Southern blot analysis revealed heterogeneous 15 normal prostate epithelial cells (CC-2555) and the LNCaP
methylation of the promoter in DU-145, PC-3 and MDAcells, but not in the DU145 or PC-3 cells as analyzed by
MB-453 cells, and homogeneous methylation of the proRT-PCR/Southern blot hybridization (middle panel).
moter in MDA-MB-231 and MDA-MB-435s cells. The
Co-amplification of a 556-bp human ~-actin message (as
prostasin gene promoter in normal human prostate epithelial
shown in the gel photograph in the lower panel) confirmed
cells, the LNCaP and the prostasin gene promoter in the 20 the quality and the quantity of the RNA applied in each
RT-PCR.
human prostate and breast cancer cell lines by Southern blot
analysis revealed heterogeneous methylation of the proExpression of prostasin protein is reduced in high-grade
moter in DU-145, PC-3 and MDA-MB-453 cells, and homohuman prostate tumor. Prostatectomy specimens from 39
geneous methylation of the promoter in MDA-MB-231 and
patients (128 sections) were subjected to immunohistochemMDA-MB-435s cells. The prostasin gene promoter in nor- 25 istry using a prostasin-specific antibody. Overall, in nonmal human prostate epithelial cells, the LNCaP and the
tumor or benign prostate epithelia, 89.0% of the examined
MCF-7 cells was shown to be unmethylated. Transfection of
areas demonstrated positive staining for prostasin protein
DU-145 and PC-3 cells with a full-length human prostasin
and 11.0% were considered negative (based on the scoring
cDNArestored prostasin expression and reduced the in vitro
system used for HercepTest™, DAKO Corporation,
invasiveness by 68% and 42%, respectively. Transfection of 30 Carpinteria, CA). In all tumor specimens that were
MDA-MB-231 and MDA-MB-435s cells with a full-length
examined, prostasin was detected in 93.3% of the low
human prostasin cDNA restored prostasin expression and
Gleason grade areas (~grade 2), 44.4% of Gleason grade 3
reduced the in vitro invasiveness by 50% for either cell line.
areas, 21.1 % of Gleason grade 4 areas, but not in Gleason
Cell proliferation was unaffected by re-expression of prosgrade 5 areas (data summarized in Table 1). The mean
tasin. Our data indicate that prostasin is implicated in normal 35 prostasin immunostaining score was found significantly
prostate biology and its down-regulation in prostate cancer,
decreased in high-grade prostate tumors as compared to
and its absence in invasive prostate and breast cancer cell
non-tumor areas (ANOVA, p<0.0001).
lines indicates increased invasiveness. Our results also indiRepresentative staining images of non-tumor (benign)
cate that delivering a functional human prostasin gene to
areas and prostate tumor areas are shown in FIGS. 4a-4l,
invasive prostate and breast cancers can reduce the inva- 40 which provides immunohistochemical detection of prostasin
s1veness.
protein in tissues. Paraffin-embedded human prostate secFor a facile understanding of the invention embodied
tions were stained for prostasin protein expression evaluaherein, reference should now be made to FIGS. 1and2. FIG.
tion using a specific antibody as described (Yu JX. Chao L.
1 sets forth a schematic for determining if a male has
Chao J. Prostasin is a novel human serine proteinase from
prostate cancer. Human blood 10 is taken from the male and 45 seminal fluid. Purification, tissue distribution, and localizaanalyzed for the presence of prostasin serine protease 14. If
tion in prostate gland. Journal of Biological Chemistry.
NO 12 prostasin is found, there is probably little or no
269(29):18843-8, 1994). Prostasin positive staining (brown
cancer. If there is a presence YES 16 of prostasin serine
color) was detected in the cytoplasm and apical membrane
protease 14, there is prostate cancer. If a biopsy of the
in non-tumor or benign epithelial cells.
prostate gland 20 is analyzed for the presence of a normal 5 0
The prostasin protein was detected in the cytoplasm and
amount YES 22 of prostasin serine protease 14, there is no
on the plasma membrane (apical) of benign epithelial cells
cancer or there is non-invasive cancer. If there is NO 24 or
lining the secretory lumen as well as in the secretion inside
Reduced 26 amount of prostasin serine protease 14, there is
the lumen (FIGS. 4A and 4B, score 3, or+++), confirming
invasive cancer.
the results of (Yu JX. Chao L. Chao J. Prostasin is a novel
FIG. 2 sets forth a schematic for determining if a female 55 human serine proteinase from seminal fluid. Purification,
has breast cancer. Human blood 100 is taken from the female
tissue distribution, and localization in prostate gland. Journal
and analyzed for the presence of prostasin serine protease
of Biological Chemistry. 269(29):18843-8, 1994). When a
140. If NO 120 prostasin is found, there is prospectively no
pre-immune rabbit serum was used in place of the prostasin
cancer. If there is a presence YES 160 of prostasin serine
antiserum, no staining was observed in either the non-tumor
protease 140, there is breast cancer. If a biopsy of the breast 60 epithelia (FIGS. 4C and 4D) or tumor epithelia (FIG. 4E).
200 is analyzed for the presence of YES 220 of prostasin
Tumor epithelia displayed various degrees of prostasin
serine protease 140, there is no invasive cancer but may be
immunostaining as shown in FIGS. 4F-4L. In Gleason grade
non-invasive cancer. If there is NO 240 or Reduced 260
1-2 tumors, moderate prostasin staining is seen in the
amount of prostasin serine protease 140, there is invasive
cytoplasm and on the plasma membrane of some epithelial
cancer.
65 cells, as well as in the secretion in the lumen (FIGS. 4G and
The levels of prostasin protein in the epithelial cells of the
4H, score 2, or ++ ). In Gleason grade 3 tumors, a lesser
human prostate gland can be used as a diagnostic marker for
number of epithelial cells displayed the moderate level
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prostasin staining (FIGS. 4I and 41). In Gleason grade 4
methylation-insensitive enzyme Msp I to yield a 951-bp
tumors, most epithelial cells did not show any prostasin
fragment for all DNA samples. The methylation-sensitive
staining, while some prostasin staining can be seen in rare,
isoschizomer Hpa II yields the 951-bp fragment in the
sporadic tumor cells (FIGS. 4K and 4L, as indicated by the
CC-2555 (normal prostate epithelial cells), the LNCaP, and
arrow, score 0). Genetically, prostate tumors are heteroge- 5 the MCF-7 samples, indicating the hypomethylated or unmneons and multi-focal in nature, in that one patient's grossethylated state of the prostasin promoter in these cells. For
anatomy tumor comes from multiple initial lesions which
DU-145, PC-3, and MDA-MB453 DNA, both the 951-bp
are caused by different initial transformation events and
and the 1,275-bp fragments are generated in the
progress to different stages by different ensuing transformamethylation-sensitive digestion, suggesting incomplete
tions (Isaacs J T. Bova GS. Prostate Cancer. In The Genetic 10 methylation (one of two or more chromosomes) or clonal
Basis of Human Cancer (Eds. Vogelstein B and Kinzler
methylation in a sub-population of cells. For the MDA-MBKW), pp653-60, McGraw-Hill Health Professions Division,
231 and MDA-MB-435, however, the Hpa II digestion did
1998). The Gleason grading, when used as a percentage of
not yield the 951-bp but rather gave the 1,275-bp fragment.
each cancer occupied by Gleason grade o/s areas, is indeThis homogeneous methylation pattern indicates that the
pendently associated with prostate cancer progression 15 Msp l/Hpa II site, at location-96 (relative to the transcription
(Stamey T A, McNeal J E, Yemoto C M, Sigal B M,
initiation site) of the prostasin promoter, is methylated
Johnstone I M. Biological determinants of cancer progres(hypermethylated) in these DNA samples.
sion in men with prostate cancer. JAMA 281:1395-1400,
Signal intensity variation may be attributed to aneuploidy.
1999). We found a significant decrease of prostasin expres(In addition to the Hpa II site at base number 1326/-96
sion in the high-grade, i.e., the more progressively trans- 20 shown in FIG. 6, example 1 and 2 are provided, more
formed tumors.
extensively detailing the other prostasin gene promoter
As earlier indicated, FIG. 5 shows human prostasin
methylated sites and experimental methods for determining
expression in human breast cancer cell lines. By means of
them. Such sites have been located at bp 615/-807, 1,102/western blot analysis (upper panel), prostasin (as a 40-kDa
320, 1,156/-266, 1,326/-96 and 1,445/+24. Nomenclature
band) was detected in MCF-7 cells, but not in MDA- 25 used in describing the nucleic acid sequences of the prosMB453, MDA-MB-231, or MDA-MB-435s cells. An equal
tasin gene are described by Yu, et al in Structure and
amount of total protein (100 µg) was loaded for each sample.
Chromosomal localization of the human prostasis (PRSS8)
At the mRNA level, human prostasin mRNA (via a 232-bp
gene. Genomics 1996:32 pp. 334-40); page 336 of the Yu,
amplified DNA band) was detected in MCF-7 and MDAet al reference is incorporated as FIG. 10 in the description
MB453 cells, but not in the MDA-MB-231 or MDA-MB- 30 of the present invention.
435s cells as analyzed by RT-PCR/Southern blot hybridizaAn examination of the prostasin gene promoter region for
tion (lower panel).
DNA methylation differences among human prostate and
Prostasin mRNAexpression is seen absent in two invasive
breast cancer cell lines has been made (see FIG. 6). We
human breast cancer cell lines while two non-invasive breast
found that cells that express prostasin, normal prostate
cancer cell lines express prostasin mRNA or protein. Analy- 35 epithelial, LNCaP, and MCF-7, are unmethylated in the
sis of prostasin expression in human breast cancer cell lines
prostasin promoter while MDA-MB-453 showed heterogeshowed that the non-invasive MCF-7 and MDA-MB-453
neous prostasin promoter methylation. For cells that do not
cells express the prostasin mRNA while the highly invasive
express prostasin, DU-145 and PC-3 showed heterogeneous
MDA-MB-231 and MDA-MB-435s cells do not express the
prostasin promoter methylation while MDA-MB-231 and
prostasin mRNA (see FIG. 5). Expression of prostasin 40 MDA-MB-435 showed homogeneous hypermethylation in
mRNA in normal human breast can be demonstrated by the
the promoter region of the prostasin gene.
presence of two GenBank™ normal human breast EST
Two human prostate cancer cell lines that do not express
sequences coding for prostasin (Accession numbers
prostasin, the highly invasive DU-145 and PC-3, show
R48653, and R48557). The MCF-7 cells also express the
prostasin protein as determined by western blot analysis 45 heterogeneous methylation in the promoter region of the
prostasin gene. The result suggests that at least one of the
(again see FIG. 5). Prostasin down-regulation in prostate or
two (or more) chromosome 16's of these cell lines is
breast cancer can be caused by promoter methylation or
methylated at the prostasin gene locus. The prostasin gene
gene-specific mutation. Prostasin expression decreases with
on
the unmethylated chromosome may contain mutations
increasing prostate cancer grade and is absent in invasive
prostate and breast cancer cell lines. The chromosomal locus 50 that silenced the expression. An alternative explanation for
the heterogeneous methylation pattern is that the methylawhere the human prostasin gene is, 16pll.2, however, is not
tion occurs in clonal cell populations, however, the lack of
known to be an LOH hot-spot in prostate cancer or in breast
detectable prostasin mRNA in our RT-PCR-Southern blot
cancer. Epigenetic events (such as DNA methylation) may
analysis in the DU-145 and PC-3 cells argues against this
be an alternative mechanism of loss of expression for tumor
possibility.
suppressors or invasion suppressors. Refer now to FIG. 6 55
The significance of the finding on prostasin gene promoter
which shows promoter hypermethylation of the human
hypermethylation in prostate or breast cancer is that the
prostasin gene in human prostate and breast cancer cell lines.
measurement of prostasin down-regulation as a cancer
Genomic DNA (5 µg) from the various cell lines (as indimarker may be achieved by using a binary assay (yes-or-no),
cated in the figure) were digested with the following restriction enzyme combinations, Xho l/BamH I (X/B, flanking 60 instead of a gradually decreasing quantity in the immunohistochemistry assay (which is quite arbitrary).
cuts of the methylation-sensitive site), Xho I/BamH l/Msp I
(X/B/M), or Xho l/BamH I/Hpa II (X/B/H). The digests
Re-expression of human prostasin protein in invasive
were resolved in a 0.8% agarose gel and transferred to an
human prostate and breast cancer cells reduces invasiveness
Immobilon-N membrane for hybridization with a nickin vitro. At this point, reference should be made to FIG. 7
translated prostasin promoter probe (bases 703-1,649 of the 65 which shows the prostasin protein expression and in vitro
invasive properties of the DU-145 and the PC-3 transfecprostasin gene sequence U33446). The probe detects a
tants. DU-145 or PC-3 cells transfected with either a vector
promoter fragment of 1,275 bp, which is cut by the
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DNA (labeled as "vector") or a prostasin cDNA construct
firmed by western blot analysis (FIG. 8, upper panel). In in
(labeled as "prostasin") were analyzed by a western blot
vitro Matrigel chemoinvasion assays, the invasiveness of
either cell lines expressing human prostasin was reduced by
analysis using a prostasin-specific antibody (upper panel) or
50% as compared to the vector-transfected controls (FIG. 8,
subjected to an in vitro Matrigel chemoinvasion assay
(lower panel) as described in (Liu DF. Rabbani SA Induc- 5 lower panel).
tion of urinary plasmiinogen activator by retinoic acid
Taken together, the foregoing evidences linking prostasin
results in increased invasiveness of human prostate cancer
level reduction or protasin absence to the invasiveness of
cells PC-3. Prostate. 27(5):269-76, 1995). The expressed
prostate and breast cancer cell lines, or linking prostasin
human prostasin protein (a 40-kDa band) was detected in the
expression to reduced invasiveness. The evidence qualifies
prostasin cDNA-transfected DU-145 or PC-3 cells, but not 10 prostasin as an invasion suppressor, which thus is a marker
in the vector-transfected cells. In the Matrigel chemoinvafor diagnosis of invasiveness of prostate and breast cancers,
sion assay, the vector-transfected cells are expressed as
or as a therapeutic agent to treat invasive prostate and breast
being 100% invasive (solid bar), the open bar represents the
cancers.
relative invasiveness of the human prostasin cDNAPathological grading by the Gleason system is performed
transfected cells. The data were analyzed by a Student t-test 15 after either surgery or biopsy, both highly invasive
using the StatView software (Abacus Concepts, Inc.,
procedures, while blood tests such as that for the PSA
Berkeley, Calif.).
prostate cancer marker can offer the hope of accurate diagIt can be seen that Polyclonal DU-145 and PC-3 cells
nosis and prognosis without the harm of an invasive procetransfected with the human prostasin cDNA (designated
dure. In practice, however, single markers suffer from an
DU-145/Pro, and PC-3/Pro, respectively) were confirmed to 20 intrinsic limitation that the "positive" identifications are not
express the human prostasin protein, as shown in the western
always confirmed for the "diagnosed" disease. Biopsy is still
blot analysis of the cell lysate (FIG. 7, upper panel). The
required for a true positive identification of prostate cancer
vector-transfected cells, designated DU-145/Vector or PC-3/
even in the case of the application of the PSA prostate cancer
Vector, respectively, were used as negative control in the
marker (Catalana W J. Partin AW. Slawin KM. Brawer M
western blot. A further examination of the DU-145/Pro and 25 K. Flanigan R C. Patel A Richie J P. deKemion J B. Walsh
the PC-3/Pro cells by immunocytochemistry confirmed that
P C. Scardino P T. Lange P H. Subong E N. Parson R E.
100% of the cells expressed the prostasin protein (data not
Gasior G H. Loveland K G. Southwick P C. Use of the
shown). In in vitro Matrigel chemoinvasion assays (FIG. 7,
percentage of free prostate-specific antigen to enhance diflower panel), the invasiveness of DU-145/Pro cells was
ferentiation of prostate cancer from benign prostatic disease:
determined to be at 32% of that of DU-145Nector cells (or, 30 a prospective multicenter clinical trial [see comments].
the reduction of invasiveness was at 68%). The invasiveness
JAMA 279(19):1542-7, 1998). As stated above, it has been
of PC-31Pro cells was determined to be at 58% of that of
demonstrated in principle that many markers used in a
PC-3Nector cells (or, the reduction of invasiveness was at
multivariate approach may provide a highly accurate diag42%). We performed in vitro cell proliferation assays on
nosis (Greene G F. Kitadai Y. Pettaway Calif. von EschenDU-145/Pro vs. DU-145Nector cells, and on PC-3/Pro vs. 35 bach AC. Bucana C D. Fidler I J. Correlation of metastasisPC-3/Vector cells, but did not observe any difference
related gene expression with metastatic potential in human
between the growth rates of the prostasin cDNA-transfected
prostate carcinoma cells implanted in nude mice using an in
or the vector-transfected cells over an 8-day period (data not
situ messenger RNA hybridization technique. American
shown).
Journal of Pathology. 150(5):1571-82, 1997). From the
Forced re-expression of human prostasin in two invasive 40 standpoint of prostate cancer genetics, the multivariate
human breast cancer cell lines reduced invasiveness. A
approach is well supported by our current understanding. A
full-length human prostasin cDNA under the control of an
serine protease structurally and genetically related to the
RSV promoter was transfected into the invasive breast
PSA, the hK2 (human glandular kallikrein 2) has shown
cancer MDA-MB-231 and MDA-MB-435 cells. Reference
some promise of joining the list of markers applicable for
should be made to FIG. 8 which shows prostasin protein 45 prostate cancer diagnosis (Saedi M S. Hill T M. Kuusexpression and in vitro invasive properties of the MDAReichel K. Kumar A Payne J. Mikolajczyk SD. Wolfert R
MB-231 and the MDA-MB-435s transfectants. MDA-MBL. Rittenhouse H G. The precursor form of the human
231 and MDA-MB-435s cells transfected with either a
kallikrein 2, a kallikrein homologous to prostate-specific
vector DNA (labeled as "vector") or a prostasin cDNA
antigen, is present in human sera and is increased in prostate
construct (labeled as "prostasin") were analyzed by a west- 50 cancer and benign prostatic hyperplasia. Clinical Chemistry.
ern blot analysis using a prostasin-specific antibody (upper
44(10):2115-9, 1998). Structurally and in prostate gland
panel) or subjected to an in vitro Matrigel chemoinvasion
biology, prostasin shares many common characteristics with
assay (lower panel) as referenced in (Liu DF. Rabbani SA
both PSA and hK2, as being a secreted serine protease made
Induction of urinary plasminogen activator by retinoic acid
in large abundance in prostate epithelial cells (Yu JX. Chao
results in increased invasiveness of human prostate cancer 55 L. Chao J. Prostasin is a novel human serine proteinase from
cells PC-3. Prostate. 27(5):269-76, 1995). The expressed
seminal fluid. Purification, tissue distribution, and localizahuman prostasin protein (a 40-kDa band) was detected in the
tion in prostate gland. Journal of Biological Chemistry.
prostasin cDNA-transfected MDA-MB-231 and MDA-MB269(29):18843-8, 1994; Yu JX. Chao L. Chao J. Molecular
435s cells, but not in the vector-transfected cells. In the
cloning, tissue-specific expression, and cellular localization
Matrigel chemoinvasion assay, the vector-transfected cells 60 of human prostasin mRNA Journal of Biological Chemistry.
are expressed as being 100% invasive (solid bar), the open
270(22):13483-9, 1995). While high-grade prostate cancer
bar represents the relative invasiveness of the human proscells produce less PSA protein than normal prostate cells or
tasin cDNA-transfected cells. The data were analyzed by a
low-grade prostate cancer cells (Hakalahti L. Vihko P.
Student t-test using the StatView software (Abacus
Henttu P. Autio-Harmainen H. Saini Y. Vihko R. Evaluation
Concepts, Inc., Berkeley, Calif.).
65 of PAP and PSAgene expression in prostatic hyperplasia and
prostatic carcinoma using northern-blot analyses, in situ
Stable, polyclonal, episomal transfectants were obtained
hybridization and immunohistochemical stainings with
and the expression of human prostasin protein was con-
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monoclonal and bispecific antibodies. International Journal
The preferred methods of separating sampled human
carcinoma tissue from neighboring normal tissues is by laser
of Cancer. 55(4):590-7, 1; Sakai H. Yogi Y. Minami Y.
Yushita Y. Kanetake H. Saito Y. Prostate specific antigen and
capture micro-dissection.
prostatic acid phosphatase immunoreactivity as prognostic;
The following examples are provided for the purpose of
Sakai H. Yogi Y. Minami Y. Yushita Y. Kanetake H. Saito Y. 5 illustration and not limitation:
Prostate specific antigen and prostatic acid phosphatase
Example 1
immunoreactivity as prognostic), the serum PSA levels in
Prostasin Promoter DNA Methylation
prostate cancer patients increase due to tissue damage
Cell Culture Maintenance
caused by invasive cancer (Rittenhouse H G. Finlay J A
All cell culture media, sera and supplements were purMikolajczyk SD. Partin AW. Human Kallikrein 2 (hK2) and
10 chased from Life Technologies (Gaithersburg, Md.) except
prostate-specific antigen (PSA): two closely related, but
for those otherwise noted
distinct, kallikreins in the prostate. [Review] [ 457 refs]
A normal human mammary epithelial cell primary culture
Critical Reviews in Clinical Laboratory Sciences. 35(4):
(catalog number CC-255) was obtained from Clonetics (San
275-368, 1998). By comparison, we also believe prostasin
Diego, Calif.) and maintained in the mammary epithelial
is in the circulation of prostate cancer patients. As a result,
a blood test for the circulating prostasin to indicate the 15 basal medium (supplemented with bovine pituitary extract,
recombinant human epidermal growth factor, bovine insulin
presence and/or the stage of prostate cancer would be highly
and hydrocortisone) according to the suppliers protocols.
useful. (as illustrated in FIG. 1). In principal, the feasibility
The Culture was kept at 37° C. with 5% C0 2 and used for
of a blood test based on prostasin detection to indicate
experiments at the 9th overall passage.
cancer has been demonstrated by Berteau et al. (1999).
Human breast carcinoma cell lines MCF-7, MDA-MB_
These authors (Berteau P. Laribi Eschwege P. Lebars I. 20
Dumas F. Benoit G. Lorie S. Prostasin mRNA to detect
453, MDA-MB-231 and MDA_MB-435 were obtained
prostate cells in blood of cancer patients. Clinical and
from the American Type Culture Collection (ATCC,
Chemical Laboratory Medicine 37 (SS): SI 19, 1999),
Manassas, Va.). The MCF-7 cells were maintained in
demonstrated a highly promising potential of using prostasin
DMEM supplemented with 10% FBS and kept at 37 for
as a marker to detect circulating prostate epithelial cells, a 25 experiments at the 9th overall passage.
sign of prostate tissue damage caused by invasive prostate
Human breast carcinoma cell lines MCF-7, MDA-MB_
cancer leading to the dissemination of prostate epithelial
453, MDA-MB-231 and MDA_MB-435 were obtained
cells into the circulation. It is expected that a blood test for
from the American Type Culture Collection (ATCC,
circulating prostasin to indicate the presence and/or the stage
Manassas, Va.). The MCF-7 cells were maintained in
of breast cancer would be highly useful. (as illustrated in 30 DMEM supplemented with 10% FBS and kept at 37° C.
FIG. 2).
with 5% C0 2 . The MDA-MB-231 and MDA-MB-453 cells
In summary of the invention, it has been taught herein
were maintained in Lebovitz-15 (L-15) medium supplethat: protein prostasin as well as its MRA levels and its gene
mented with 10% FBS and kept at 37° C. without C0 2 . The
promoter DNA methylation levels can be used to determine
MDA-MB-435 cells were maintained in L-15 medium
the invasiveness level of human carcinomas; and, provide a 35 supplemented with 15% FBS and 10 µg/ml bovine insulin
method of treating invasive human carcinomas by delivery
and kept at 37° C. without C0 2 .
thereto of a recombinant nucleic acid formed by a human
Transfection Of Cell Lines With Plasmid DNA And
prostasin nucleic acid incorporated into a selected gene
Selection Of Stable Transfectants
delivery vector. Those teachings are repeated for emphasis
Construction of a plasmid containing a full-length human
in the following:
40 prostasin cDNA under the control of a Rous sarcoma virus
1. Immunohistochemistry studies of human prostate can(RSV) promoter and transfection of cells were carried out as
cer specimens revealed a down-regulation of prostasin
described in Chen, L M, Hodge, G B, Guarda, L A et al.
in high-grade tumors.
Down-Regulation of Prostasin Serine Protease, A potential
2. Using RT-PCR and western blot analyses, prostasin
Invasion Suppressor in Prostate Cancer, Prostrate 2001,
protein and mRNA expression were found in a non-invasive 45 48:93-103. Briefly, 1,000,000 MDA-MB-231 or MDA-MBhuman breast cancer cell line, MCF-7, while invasive human
435s cells were resuspended in 0.3 ml of the culture medium
breast cancer cell lines MDA-MB-231 and MDA-MB-435s
and mixed with 50 µg of plasmid DNA dissolved in 0.1 ml
were found not to express either the prostasin protein or the
of sterile distilled cuvette and pulsed at 200 volts, 1,600 µF,
mRNA. A non-invasive human breast cancer cell line,
72 ohms and 500 V/capacitance setting on a BTX-600
MDA-MB-453, was shown to express prostasin mRNA but 50 Eleciro-cell manipulator (Genetronics, San Diego, Calif.).
not prostasin protein: and,
Selection of transfectants was carried out in the presence of
800 µg/ml G418 (final concentration) until colonies
3. Examination of the prostasin gene promoter in the
human prostate and breast cancer cell lines by Southern
appeared. (5-7 days) Colonies (""200 in number) were then
blot analysis revealed heterogeneous methylation of the
dispersed via trypsinization and maintained in G418 conpromoter in DU-145, PC-3 and MDA-MB453 cells, 55 taining culture medium without colony-isolation. Cells
transfected with the human prostasin cDNA construct were
and homogeneous methylation of the promoter in
MDA-MB-231 and MDA-MB-435s cells. The prostaassayed in Western blot analysis for expression of the
sin gene promoter in normal human prostate epithelial
prostasin protein, using vector-transfected cells as controls.
cells, the LNCAP and the MCF-7 cells was shown to be
RNA Preparation And Analysis By RT-PCR(Southern
unmethylated. Transfection of DU-145 and PC-3 cells 60 Blot
Cells grown to 80% confluence (in 60 nm tissue culture
with a full-length human prostasin cDNA restored
prostasin expression and reduced the in vitro invasivedish) were lysed directly with 1 ml of the Trizol Reagent
ness by 68% and 42%, respectively. Transfection of
(life Technologies) and RNA was isolated according to the
MDA-MB-231 and MDA-MB-435s cells with a fullmanufacturer's protocol. The human prostasin-specific
length human prostasin cDNA restored prostasin 65 RT-PCR/Southern blot analysis was performed as described
in Yu, J X, and Chao,J Molecular Cloning, tissue-specific
expression and reduced the in vitro invasiveness by
expression and cellular localization of human prostasin
50% for either cell line.
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mRNA. J Biol Chem 1995; 270:12483-4. One microgram of
Genomic Southern Blot Analysis Of Prostasin Promoter
Methylation
total RNA was used in the RT-PCR with 2 human prostasin
High molecular weight genomic DNA was isolated from
gene-specific oligonucleotide primers, and a Southern blot
various cell lines as described in Chai, K X, Ward, D C,
of the resolved RT-PCR samples was probed with a third
prostasin gene-specific oligonucleotide, detecting an ampli- 5 Chao, J, et al Molecular Clonings Sequence Analysis and
Chromosomal Localization of the Human Protease Inhibitor
fied 232 bp fragment. A co-amplification of the ~-actin
4 (kallistatin) gene (P14) Genomics 1994; 23:370-8.
mRNA for control of RNA quality and quantity was perGenomic DNA frm each cell line was digested with the
formed as described in Chen Hodge and Guarda, et al.
following restriction enzyme combinations:Xho I/BamH I
Western Blot Analysis
(X/B), Xho I/BamH l/Hha (X/B/Hh), Xho I/BamH l/Aci I
10
(X/B/A), Xho I/Barn H I.Bsa I (X/B/Bs),Xho I/Barn H l/Msp
Cells grown to 80--100% confluence were washed 3 times
I(X/B/M) or Xho I/Barn H l/Hpa II(X/B/H) using 10 µg of
in lxPBS (pH 7.4) and then lysed in RIPA buffer (lxPBS,
DNA per digestion combination. The X/B cutting sites flank
pH 7.4, 1 % NP-40, 0.5% sodium deoxycholate, 0.1 % SDS).
the CpG sies be to be investigated for differential methylaThe total lysate were centrifuged at 14,000 rpm for 30
minutes at 4 ° C. to remove the pellet. Protein concentration 15 tion by the methylation-sensitive restriction endonucleases.
The digests were resolved in a 0.8% agarose gel and
was determined using a DC (detergent-compatible) protein
analyzed by Southern blot hybridization as described in
assay kit (Bio-Rad, Hercules, Calif.). The samples were then
Chai, K X, Ward, D C, Chao, J et al. A nick translated
subjected to SDS-PAGE followed by Western blot analysis
prostasin promoter probe (bases 703-1,649) of the prostasin
using a prostasin-specific antibody. Briefly, cell lysate were
resolved in 10% gels under reducing conditions before 20 gene sequence, Genbank accession number U33446) was
used for the hybridization. The base numbering of the
electrotransfer to nitrocellulose (NC) membranes (Fisher
prostasin gene sequence was described in Yu et al.
Scientific, Pittsburgh, Pa.). Upon complete protein transfer,
Demethylation of Prostasin Gene Promoter and Reactivation
the NC membranes were blocked in BLOTTO (5% nonfat
of Prostasin Expression
milk made with Tris-buffered saline/0.1 % Tween-20, pH
For demethylation of prostasin gene promoter, MDA7.6), incubated with the prostasin-specific antibody diluted 25
MB-231 and MDA-MB-435s cells were seeded in 100 mm
at a ratio of 1:2000 in BLOTTO, followed by an incubation
dishes at an initial density of 50% confluence and cultured
with the secondary antibody, goat antirabbit IgG conjugated
in the presence of 500 nM 5-aza-2'-deoxycytidine (5-azato HRP (horseradish peroxidase; used at 1:10,000) (Sigma2'dC; Sigma-Aldrich) for 8 days with renewal of medium
Aldrich, St. Louis Mo.). The bound secondary antibody was
detected using enhanced chemi-luminesence (ECL) reagents 30 and 5-aza-2'-dC performed at 2 day intervals. Genomic
DNA was then isolated for Southern blot analysis as
(Pierce, Rockford, Ill.) according to the suppliers recomdescribed. For reactivation of prostasin expression, MDAmendations. All procedures were performed at room
MB-231 and MDA-MB-435s cells were seeded in 60 mm
temperature, and the membranes were washed between
dishes at 80% confluence and cultured in the presence of 500
steps.
nM 5-aza-2'-dC for 24 hr, and were then treated for an
Matrigel Chemoinvasion Assay
35
additional 24 hr with either 1 µM trichostatin A(TSA; Sigma
The Matrigel chemoinvasion assay was carried out essenAldrich) or an equal volume of 95% ethanol used to dissolve
tially as described in Chen, L. M., Hodge, GB, Guardia, LA
TSA. For measuring time-dependence of prostatin gene
et al. Down-Regulation of prostasin serine protease, a potenreactivation, cells were treated as described above but were
tial invasion suppressor in prostate cancer. Prostate
2001:48:93-103, incorporated herein. Basement membrane 40 harvested at 6 or 12 hr after the addition of TSA. RNA was
isolated for prostasin-specifric RT-PCR/Southern blot analyMatrigel stock (10 mg/ml; Collaborative Biochemical,
sis as described. The MCF-7 and the MDA-MB-453 cell
Bedford, Mass.) was thawed overnight on ice in a refrigines were subjected tot the same 5-aza-2'-dC/TSA treatment
erator (0-4° C.). Transwell invasion chambers (Coster,
and prostasin RT-PCR Southern blot analysis procedures.
Cambridge, Mass.) with 8 µm pore polycarbonate filters
2
(growth area 0.33 cm ) were coated with Matrigel (50 45
Results
Prostasin Expression In Breast Cancer Lines
µg/filter, a 1:3 dilution of the stock with chilled serum-free
Expression of prostasin protein and mRNA in Normal
medium was used for coating). The gels were solidified by
incubating the coated filters at 37° C. for 60 min in a moist
Human Mammary Epithelial Cells (NHMEC) and human
breast carcinoma cell lines was examined by Western blot
chamber before use. The lower chambers of the Transwell
plates were filled with 0.6 ml serum-free medium (1-15), 50 analysis using a prostasin-specific antibody or RT-PCR/
Southern blot analysis as described. For this experiment 4
supplemented with 25 µg/ml fibronectin (Sigma-Aldrich).
Fifty thousand cells in 0.1 ml serum-free OPTI-MEM I
breast carcinoma cell lines based on their differences in
invasiveness and metastatic potential were chosen. The
medium were placed onto each Matrigel-coated filter. The
MCF-7 cell line is poorly invasive to noninvasive, tumorifilter cartridge was then inserted into the lower chamber and
the assays were performed at 37° C. for 24 hours (MDA- 55 genic but nonmetastatic. The MDA-MB-453 cells are poorly
tumorigenic and nonmetastatic. The MDA-MB-231 and
MB-435s transfectants) or 72 hour (MDA-MB-231
MDA-MB-435 cells are both highly invasive and highly
transfectants). After removing the medium, the filters were
metastatic.
washed 3 times in lxPBS, fixed at room temperature for 20
min in 4% paraformaldehyde made with 0.1 M sodium
As was shown in FIG. 5 (middle panel) a 232 bp amplified
phosphate buffer (pH 7.4) and then washed 3 times with the 60 prostasin message was detected in total RNA of NHMEC,
MCF-7 and MDA-MB-453 but not MDA-MB-231 or MDAsodium phosphate buffer. The filters were then stained with
1 % toluidine blue (LabChem, Pittsburgh, Pa.) for 2 min. The
MB-435s. A co-amplification of ~-actin message is shown in
cells on the Matrigel surface were removed with a Q-tip and
the bottom panel of FIG. 5 to demonstrate the quality and
quality of total RNA used in each RT-PCR. In addition to the
all cells on the underside of the filters were counted under a
light microscope after mounting the filter on a glass slide. 65 expected 232 bp prostasin amplification product, a faint
All invasion assays were done in triplicate for at least 3
bank of retarded mobility was also detected in the Southern
times.
blot analysis. This retarded band does not represent a new
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prostasin message, but rather is a single-stranded form of the
expected prostasin PCR product. In a separate experiment,
we were able to remove this single-stranded form by treating
the PCR products with SI nuclease prior to electrophoresis
(data not shown)
Re-expression of recombinant human prostasin in invasive
breast cancer cells reduced in vitro invasiveness
Following the electroporation and drug selection ""200
colonies formed for each transfected cell type. All colonies
for each transfected cell type were kept in a mixed culture
as polyclonal transfectants for the ensuing experiments.
Polyclonal MDA-MB-231 and MDA-MB-435s cells transfected with the human prostasin cDNA were confimred to
express the recombinant human prostasin protein, as shown
by Western blot analysis of the cell lysate (FIG. 8, top panel)
The vector transfected cells were used as negative control in
the Western blot analysis.
In the in vitro Matrigel chemoinvasion assays shown in
FIG. 8, bottom panel) transfected MDA-MB-231 or MDAMB-345s cells expressing the recombinant human prostasin
protein showed a significantly reduced level of invasiveness,
at 50% of that of their vector transfected controls, respectively.
Prostasin Gene Promotor Is Hypermethylated In Invasive
Breast Cancer Lines
Examination of the prostasin gene locus by genomic
Southern blot-RFLP (restriction fragment length
polymorphism) analysis did not reveal any evidence of gene
loss or gross rearrangement in the cell lines that did not show
prostasin expression, namely, MDA-MB435 (data not
shown) Consideration of the possibility of prostasin genesilencing by epigenetic mechanisms was also considered.
Polysynthetic methylation of cytosine residues in the 5'-CpG
islands is often involved in long-term silencing of certain
genes during mammalian development and in the progression of cancers. An examination of the prostasin promoter
and exon I region sequence (GenBank accession number
U33446) identified 28 CpG dinucleotides in a segment
defined by an Xho I site (vse number 374 of U33446 or
-1,048 relative to the transcription initiation site and a
BamH I site (base number 1,649 of U33446 or +228 relative
to the transcription initiation site) (FIG. 9a*) A GC enriched
domain containing 2 consensus G/C boxes with the
sequence GGGCGG was identified as encompassing the
transcription initiation site. This GC enriched domain
extends from base number 1,101 to the BamH I site (1,649)
as a length of 549 bp and has a GC content of 58.6%. The
549 bp QC-enriched domain contains 19 CpG dinucleotides,
but failed to qualify as a true CpG island by the standards of
Gardiner-Garden, M, and Frommer, M. CpG islands in
vertebrate genomes. J Mol Biol 1987:196:261-82.
In all breast cancer cell lines and the NHMEC, Xhol/
BamH I/Hha digestion yielded a 1,275 bp prostasin promoter band seen in the Xho I/BamH I/I digestion (**FIG. 9b
upper panel) indicating that the -807 Hha I site-CpG is
homogenously methylated.
In the NHMEC digestion with Xho I/Barn H l/Aci I
yielded a 1,072 bp, a 727 bp and a 345 bp band, but no 1,275
bp band, indicating that the -320 Aci I site-CpG is heterogeneously methylated but the +24 Aci I site CpG is homogenously unmethylated. In MCF-7, MDA-MB-453 and
MDA-MB-231, digestion with Xho I/BamH l/Aci I yielded
only the 1,072 bp band, indicating that the -320 Aci site
CpG is homogenously methylated, but the +24 Aci site CpG
is homogenously unmethylated. In MDA-MB-435s, digestion with Xho l/BamH/Aci I yielded only the 1,275 bp band,
indicating that both the -320 and the +24 Aci I site CpG's
are homogenously methylated.

In NHMEC and MCF-7 cells the 1,275 bp Xho I/BamH
I band can be digested by the methylation-insensitive Msp I
as well as by the methylation sensitive Hpa II yielding an
951 bp band, indicating that the CpG at the -96 M/H
restriction site is homogenously unmethylated. In MDAMB-453, the 1,275 bp band can be fully digested by Msp I
but only partially by Hpa II indicating heterogenous methylation of the -96 M/H site CpG. In MDA-MB-231 and
MDA-MB-435s, the 1,275 bp band was undigested by Hpa
II while having been completely digested by Msp I, indicating that the -96 M/H site CpG is homogenously methylated.
Overall, in the prostasin-expressing cells the NHMEC is
the least methylated in this region and the methylation is
restricted to beyond -266 relative to the transcription initiation site. The prostasin gene promoter-exon I region in
MCF-7 and MDA-MB-453 cells is methylated to a higher
extent than that in the NHMEC. In the MCF-7, methylation
is restricted to beyond -966, while in the MDA-MB-453,
methylation is observed at the -96 position and beyond. In
the cells that do not express prostasin, the promoter-exon I
region is the most heavily methylated. While in MDA-MB231 the methylation is still restricted to the 5'fianking region,
all CpG sites examined, including 1 of exon 1 ( +24 Aci I site
CpG) were found to be homogenously methylated in the
MDA-MB-435s cells. The results showed that the prostasin
gene promoter-exon 1 region CpG methylation patterns
correlate with the absence of prostasin expression in the
human breast cells examined.
Prostasin Expression Was Reactivated By Demethylation
And Histone Dacetylase Inhibition In The Invasive And
Metastatic Breast Cancer Cell Lines
Methylated promoter DNA may contribute to repression
of gene expression by interfering with the binding of transcription factors, or by interacting with various methyl-CpG
binding proteins. Such as the McCP 1 complex, MeCP2 and
the MBD's depending on cell type, sequence of the methylated regulatory region and binding of other transcription
factors. Histone deacetylases are recruited by the methylCpG binding proteins to co-repress gene expression via
chromatin restructuring. Histone deacetylases act synergistically with DNA methylation in the co-repression, with
DNAmethylation being the dominant force for stable maintenance of gene silencing in cancer. Treatment of cancer
cells with the demethylation agent 5-aza-2'-deoxycytidine
(5-aza-2'dC) may restore a minimal expression for genes
silenced by promoter methylation and the combined treatment of 5-aza-2'-dC with the histone deacetylase inhibitor,
trichostatin A (TSA) may further stimulate the restored
expression. Investigation of demethylation and/or histone
deacetylase inhibition could reactive prostasin gene expression in the MDA-MB-231 and MDAA-MB-435s cells proceeded as follows:
After 8 days of treatment with the DNAmethyltransferase
inhibitor 5-aza-2'-dC, a significant level of demethylation
was observed in the prostasin promoter-exon 1 region in the
MDA-MB-435s cells, as genomic DNA of this region in
these cells was partially digested by Hha I at -807, Aci I at
-320, BsaAI at -266 and Hpa Hat -96 (***FIG. 9c). The
+24 Aci I was also partially digested in MDA-Mb-435s
following demethylation (FIG. 9c) Examination of total
RNA of these cells by RT-PCR/Southern blot analysis following the 8-day 5-aza-2'-dC treatment, however, failed to
detect prostasin mRNA expression (data not shown).
Investigation of the combined effect of treating the cells
with 5-aza-2'-dC and TSA, an inhibitor of histone deacetylase followed. In RT-PCR/Southern blot analysis, a time-
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dependant reactivated expression of prostasin mRNA was
Cell Culture Maintenance
observed in both the MDA-MB-231 and the MDA-MB-435s
A normal human prostate epithelial cell (PrEC) primary
cells after a treatment with 5-aza-2'-dC for 24 hr followed by
culture (PrEC primary culture (Catalog Number CC-2555)
95% ethanol (solvent for TSA) did not result in prostasin
was obtained from Clonetics (San Diego, Calif.) and mainmRNA re-expression. A co-amplification of the ~-actin 5 tained in the supplied medium (prostrate epithelial cell basal
message confirmed the quality and quantity of the total RNA
medium, containing bovine pituitary extract,
used in each RT-PCR. When MCF-7 and MDA-MB-453
hydrocortisone, human epidermal growth factor,
cells were subjected to the same 5-aza-2'-dC/TSA treatment
epinephrine, transferring, insulin, retinoic acid, triand prostasin RT-PCR/Southern blot analysis procedures, no
iodothyronine, gentamicin, and amphotericin). The culture
increase of prostasin mRNA expression was observed for
was kept at 37° C. with 5% C0 2 and used for experiments
10
either cell line.
at the overall passage.
FIG. 9a The solid horizontal line represents the promoterHuman prostate cancer cell lines LNCAP, DU-145 and
exon I region of the human promstasin gene (Genbank
PC-3 were obtained from the American Type Culture ColU33446) The Xho I site is located at Base 1,649 of the
lection (ATCC, Manassas, Va.). The PC-3 cells were mainU33446 sequence respectively. The methylation sensitive
restriction sites used for differential methylation analysis, 15 tained in F-12K medium supplemented with 10% fetal
bovine serum (FBS) while the LNCaP and the DU-145 cells
Hha (615/-807), Aci I (1,102/-320 and 1,445/+24), BsaA I
were maintained in RPMI-1640 medium supplemented with
(1,156/-266) and Msp l/Hpa II (1,326/-96) are indicated by
10% FBS and 1 mM sodim pyruvate, and all were kept at
arrows. Four additional Aci I sites and a second dMsp Ihpa
37° C. with 5% C0 2 .
Ii site are present between the +24 Aci I site and the Barn H
Demethylation Of Prostasin Gene Promoter And ReactiI sies but not shown in the figure since they do not affect the 20
vation Of Prostasin Expression
results of the genomic DNA Southern blot analysis. The
Du-145 and PC-3 cells were seeded in 60-mm dishes at
transcription initiation site is indicated by the triangle on an
80% confluence and cultured in the presence of 500 nM
extended vertical bar. The vertical bars map the location of
5-aza-2'-dC for 24 hours and were then treated for an
the 28 CpG dinucleotides identified in this region. A 549 bp
GC-enriched domain is indicated by the filled rectangular 25 additional 24 hours with either 1 µM trichostatin A (TSA,
Sigma-Aldrich Co.) or an equal volume of 95% ethanol used
box. The extended vertical bas with open square boxes
to dissolve TSA. TNA was isolated for prostasin-specific
indicate the locations of the consensus G/Cboxes. The
RT-PCR/Southern blot analysis as described in example 1.
location of the probe used in the genomic DNA Southern
As in example 1, the prostate cells were subjected to
blot analysis is shown by the open rectangular box.
FIG. 9b. Panels of genomic DNA Southern lot analysis 30 Southern blot analysis. In all three prostate cancer cell lines
and the PrEC, XhoI/BamH I/Hha I digestion yielded a 1,275
results are as indicated for each cell type. Restriction endobp prostasin promoter band seen in the XhoI/BamH I/Hha I
nucleases used in each digestion mixture are indentified as
digestion (FIG. 10, upper panel), indicating that the -807
follows: X, Xho I, B, Barn H I, Hh, Hha I, A, Aci I, Bs, BsaA
Hha site-CpG is homogeneously methylated.
I, M, Msp I, H, Hpa II. Hha I, Aci I, BsaA I and Hpa II only
In the PrEC, digestion with Xho I/Barn H l/Aci I yielded
cut unmethylated DNA while Msp I, an isoschizomer of Hpa 35
a 1,072 bp, a 727 bp and a 345 bp band, but no 1,275 bp band
Ii, cuts unmethylated or methylated DNA Genomic DNA
indicating that the -320 Aci I site CpG is heterogeneously
(10 µg) from each cell type was cut with X/B or with XIB/M
methylated but the +24 Aci site CpG is homogeneously
to serve as controls for the detection of differential methyunmethylated.
In LNCaP and Du-145, digestion with Xho
lation. In the upper panel, prostasin promoter DNA will
yield a 1,275 bp X/B fragment. When Hha I was added to the 40 l/BamH l/Aci I ielded only the 1,072 bp band indicating that
the -320 Aci I site-CpG is homogenously methylated but the
X/B digestion mixture a fragment of 1,037 bp was expected
+24 Aci I site CpG is homogeneously unmethylated. In
if the -807 Hha I site CpG was not methylated. When Aci
PC-3,
digestion with Xho I/BamH l/Aci I yielded the 1,072
I was added to the X/B digestion mixture, 3 smaller bands
bp band and to a lesser extent the 1,275 band, indicating that
might be expected depending on CpG methylation states at
-320 and +24 Aci I sites. They are 1,072 bp(from Xho I to 45 the -320 Aci I site-CpG is homogensously methylated,
while the +24 Aci I site pG is heterogeneously methylated.
+24 Aci I) 727 bp (from Xho I to -320 Aci I) and 345 bp
In the PrEC and LNCaP digestion with Xho I/BamH
(from -320 Aci to +24 Aci I) in length, respectively. When
l/BsaA I yielded a 782 bp and a 493 bp band, indicating that
BsaA I was added to the X/B digestion mixture, 2 smaller
the -266 BsaA I site CpG is homogeneously unmethylated.
bands might be expected depending on CpG methylation
state at the -266 Bsa A I. They are 782 bp (from Xho I to 50 In DU-145, digestion with Xho l/BamH I/BasAI yielded the
782 bp and the 493 bp bands, but also the 1,275 bp band,
BsaA I) and 493 bp (from BsaA I to BamH I) in length,
indicating that the -266 BsaAI site-CpG is heterogeneously
respectively (indicated by asterisks in the figure). In the
methylated. In PC-3, digestion with Xho/BamH l/BsaA I
lower panel, the upper arrow points to the X/B fragment,
yielded only the 1,275 bp band, indicating that the -266
while the lower arrow points to the fragment that is generated by Msp I, regardless of DNAmethylation, or by Hpa LI, 55 BsaA I site-CpG is homogeneously methylated.
In the PrEC and LNCaP cells, the 1,275 bp Xho I-BamH
only when DNA is unmethylated.
I band can be digested by the methylation-insensitive Msp I
FIG. 9c Cells treated with 5-aza-2'dC for 8 days were
as well as by the methylation-sensitive Hpa II, yielding a
harvested for genomic DNA isolation and southern blot
951 bp band (FIG. 10, lower panel) indicating that the CpG
analysis as described. The arrowhead indicates the 1,037 bp
Hha I-BamH I fragement when the -807 ha I site was cut by 60 at the -96 M/H restriction site is homogeneously unmethylated. In DU-145 and PC-3, the 1,275 bp band can be fully
enzyme following DNA demethylation.
digested by Msp I but only partially by Hpa II (FIG. 10,
Example 2
lower panel) indicating heterogeneous methylation of the
The same methylated sites investigated in example I
-96 M/H site Cpg.
above in breast cancer cell lines, were investigated in human 65
The PrEC express both the prostasin mRNA and protein
and is the least methylated in the prostasin promoter-exon 1
prostate cancer cell lines and human prostate epithelial cells.
region (methylation is only observed at beyond -266 relaAll methods were the same, except as follows:
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prostasin expression in the invasive prostate cancer cells, the
tive to the transcription initiation site. The prostasin gene
promoter-exon 1 region in LNCaP cells is methylated to a
reactivated expression represents only the basal expression,
higher extent than that in the PrEC. In LNCaP, which also
similar to what was observed in the breast cancer cells.
express both the prostasin mRNA and protein, methyltion is
Examples I and II demonstrate that the methylation patonly observed at beyond -96. In DU-145, which does not 5 terns of the same specific sites in both breast cancer and
express either the prostasin protein or mRNA, the promoterprostate cancer provide markers for invasiveness.
exon 1 region is the most heavily methylated. While in
While the invention has been described, disclosed, illusDU-145, the methylation is limited to the 5 flanking region,
trated and shown in various terms of certain embodiments or
all CpG sites examined, including one of exon 1 ( +24 Aci I
modifications which it has presumed in practice, the scope
site-CpG) show heterogeneous to homogeneous methylation
10 of the invention is not intended to be, nor should it be
in the PC-3 cells. The prostasin gene promoter-exon region
deemed to be, limited thereby and such other modifications
CpG methylation patterns correlate with the absence of
or embodiments as may be suggested by the teachings herein
prostasin expression in the human prostate cells.
are particularly reserved especially as they fall within the
Table I details the methylation state of the prostate cells.
breadth and scope of the claims here appended.
As shown with the breast cancer cells the methylation state
We claim:
of the prostasin promoter region may be examined for a 15
1. A method for determining whether human prostate or
potential diagnostic application to indicate prostate cancer
breast carcinomas are non invasive, comprising sampling
invasiveness. For example, the prostasin gene promoter
human breast or prostate carcinomas and determining
methylation state at the -96M/H CpG site, for example, is
whether the prostasin gene promoter DNA is methylated at
seen methylated in invasive cell types.
20
bp 1,156/-266, wherein the absence of methylation indicates
a non-invasive carcinoma.
TABLE 1
2. The method, as in claim 1 wherein the sampling of the
CpG methylation in the prostasin gene promoter-exon1 region in human
carcinoma tissue includes the step of separating the human
rostate cells.
carcinoma tissue from neighboring normal tissue using a
25
laser capture micro-dissection.
Prostasin
Mspl/
3. The method, as in claim 1, wherein the step of deterHha 1
Aci 1
BsaA 1
Hpa 11 Acl 1
Cell
Exp resmining gene promoter DNA methylation patterns includes
Type
sion
(-807)
(-320)
(-266)
(-96)
(+24)
applying prostasin-promoter-specific oligonucleotide primers in a PCR to determine the prostasin gene promoter DNA
UnUnPr EC
Yes
Methyl Hetero- Un-Methyl
30
Methyl Methyl
methyl
methylation patterns in the sampled tissue.
UnUnLNCaP Yes
Methyl Methyl Un-Methyl
4. A method for determining which cancer patients do not
Methyl Methyl
require chemotherapeutic treatment, comprising taking a
Hetero- UnDU-145 No
Methyl Methyl Heterobiopsy of a prostate or breast tumor, and determining the
Methyl
Methyl Methyl
Hetero- HeteroPC-3
No
Methyl Methyl Methyl
non-invasiveness of the carcinoma tissue based on the
Methyl Methyl
35
absence of methylation of the prostasin gene promoter DNA
at bp 1,156/-266.
Table Legend:
5. A method for determining whether human prostate
Methyl ~ homogeneously methylated
Hetero-Methyl ~heterogeneously methylated
carcinomas are non invasive, comprising sampling human
Un-Methyl ~ homogeneously unmethylated
prostate carcinomas and determining whether the prostasin
40
gene promoter DNA is methylated at bp 1,156/-266,
In investigating whether methylation in the promoter is
wherein the absence of methylation indicates a noncausal to the lack of prostasin gene expression in the
invastive caarcinoma and the presence of methylation indiDU-145 and PC-3 cells, as in the breast cancer cells,
cates invasive carcinoma.
treatment of these cell lines for 8 days with the DNA
6. The method of claim 5 wherein the sampling of the
methyltransferase inhibitor 5-aza-2'-dC resulted in signifi45
carcinoma tissue includes the step of separating the human
cant level of demethylation but no prostasin mRNA exprescarcinoma tissue from neighboring normal tissue using a
sion was detected in an RT-PCR/Southern blot analysis of
laser capture micro-dissection.
the DNA demethylated cells. Treatment of the cells with the
7. The method of claim 5, wherein the step of determining
combination of 5-aza-2'-dC and trichostatin A (TSA) an
inhibitor or histone deacetylase however restored prostasin 50 gene promoter DNA methylation patterns includes applying
prostasin-promoter-specific oligonucleotide primers in a
mRNA expression in DU-145 and PC-3 cells (data not
PCR to determine the prostasin gene promoter DNAmethyshown) When investigating whether the prostasin protein
lation patterns in the sampled tissue.
was expressed in the 5-aza-2'dC/TSA treated cells by western blot analyis, the result was negative. It appears that
although promoter DNAmethylation is causal to absence of
* * * * *

